GT201600131A - Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis - Google Patents

Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis

Info

Publication number
GT201600131A
GT201600131A GT201600131A GT201600131A GT201600131A GT 201600131 A GT201600131 A GT 201600131A GT 201600131 A GT201600131 A GT 201600131A GT 201600131 A GT201600131 A GT 201600131A GT 201600131 A GT201600131 A GT 201600131A
Authority
GT
Guatemala
Prior art keywords
triazolo
pyrimidine
leishmaniasis
derivatives
treatment
Prior art date
Application number
GT201600131A
Other languages
English (en)
Spanish (es)
Inventor
Biggart Agnes
Liang Fang
Jacob Nelson Mathison Casey
Molteni Valentina
Suresh Nagle Advait
Yeh Vince
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52302387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201600131(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201600131A publication Critical patent/GT201600131A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
GT201600131A 2013-12-19 2016-06-17 Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis GT201600131A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361918089P 2013-12-19 2013-12-19

Publications (1)

Publication Number Publication Date
GT201600131A true GT201600131A (es) 2018-12-18

Family

ID=52302387

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600131A GT201600131A (es) 2013-12-19 2016-06-17 Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis

Country Status (41)

Country Link
US (6) US9303034B2 (zh)
EP (1) EP3083627B1 (zh)
JP (1) JP6392352B2 (zh)
KR (1) KR102354082B1 (zh)
CN (1) CN106029666B (zh)
AP (1) AP2016009329A0 (zh)
AR (1) AR098844A1 (zh)
AU (1) AU2014364565B2 (zh)
BR (1) BR112016014004B1 (zh)
CA (1) CA2932870C (zh)
CL (1) CL2016001421A1 (zh)
CR (1) CR20160334A (zh)
CU (1) CU24379B1 (zh)
CY (1) CY1121060T1 (zh)
DK (1) DK3083627T3 (zh)
EA (1) EA030823B1 (zh)
EC (1) ECSP16067921A (zh)
ES (1) ES2701087T3 (zh)
GT (1) GT201600131A (zh)
HR (1) HRP20182021T1 (zh)
HU (1) HUE040254T2 (zh)
IL (1) IL246034B (zh)
LT (1) LT3083627T (zh)
MA (1) MA39186A1 (zh)
MX (1) MX368072B (zh)
MY (1) MY175865A (zh)
NZ (1) NZ721650A (zh)
PE (1) PE20160865A1 (zh)
PH (1) PH12016501198A1 (zh)
PL (1) PL3083627T3 (zh)
PT (1) PT3083627T (zh)
RS (1) RS58053B1 (zh)
SG (1) SG11201604618TA (zh)
SI (1) SI3083627T1 (zh)
SV (1) SV2016005226A (zh)
TN (1) TN2016000253A1 (zh)
TW (1) TWI674263B (zh)
UA (1) UA117046C2 (zh)
UY (1) UY35903A (zh)
WO (1) WO2015095477A1 (zh)
ZA (1) ZA201604415B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170546A (es) 2015-05-29 2018-04-02 The Univ Of Dundee Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios
SI3331885T1 (sl) * 2015-08-07 2021-03-31 Glaxosmithkline Intellectual Property Development Limited Spojine
US10399966B2 (en) 2016-01-21 2019-09-03 University Of Washington Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
TW202028208A (zh) 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
FR2652085A1 (fr) 1989-09-20 1991-03-22 Science Organisation Nouveau procede de synthese de derives d'oxazolopyridines.
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0643588A (ja) * 1992-07-27 1994-02-18 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3735741B2 (ja) * 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
AU4499697A (en) * 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US20030225036A1 (en) 2000-03-20 2003-12-04 Aleksandr Kolesnikov Non-amidine containing protease inhibitors
AU2001259707A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
AU2002216649A1 (en) 2000-10-31 2002-05-15 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
WO2002044126A2 (en) 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
PL366799A1 (en) 2001-07-27 2005-02-07 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
EP1452528B1 (en) 2001-11-16 2008-08-13 Nippon Chemiphar Co., Ltd. Xanthine oxidase inhibitors
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CA2534292A1 (en) * 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
EP1651198A2 (en) 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
WO2005030206A1 (en) 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
CN1930159A (zh) 2004-03-08 2007-03-14 北卡罗来纳大学查珀尔希尔分校 作为抗原生动物药的新的双阳离子咪唑并[1,2－a]吡啶和5,6,7,8－四氢－咪唑并[1,2－a]吡啶化合物
WO2006066914A2 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
WO2007017143A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
EP1912987A1 (en) 2005-08-01 2008-04-23 F. Hoffmann-Roche AG Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
WO2007019346A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
CA2656810C (en) 2006-07-11 2012-03-13 Daewoong Pharmaceutical Co., Ltd. Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008100376A2 (en) 2007-02-15 2008-08-21 Sirtris Pharmaceuticals, Inc. Truncation variants of sirt1 and methods of use thereof
CA2681813A1 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
MX2009011208A (es) 2007-04-19 2009-10-30 Novartis Ag Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2009051454A2 (en) 2007-10-17 2009-04-23 Cheil Industries Inc. Novel compound for organic photoelectric device and organic photoelectric device including the same
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
ES2797955T3 (es) 2008-08-25 2020-12-04 Novartis Ag Moduladores de la ruta de hedgehog
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
UY32776A (es) * 2009-07-09 2011-02-28 Irm Llc Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
ES2527835T3 (es) * 2009-09-29 2015-01-30 Board Of Regents, The University Of Texas System Agentes anti malaria que son inhibidores de dihidroorotato deshidrogenasa
JP5937968B2 (ja) * 2010-01-29 2016-06-22 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。
CA2837818A1 (en) 2010-06-03 2011-12-08 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (cns) injury
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012130633A1 (en) 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
AU2012335088B2 (en) 2011-11-11 2017-08-24 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
ES2579981T3 (es) * 2012-03-07 2016-08-18 Merck Patent Gmbh Derivados de triazolopirazina
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TW201406736A (zh) 2012-06-28 2014-02-16 Fujifilm Corp 新穎的醯胺衍生物或其鹽
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
DK2888251T3 (da) 2012-08-21 2019-07-29 Peter Maccallum Cancer Inst Perforinhæmmende benzensulfonamidforbindelser, fremstilling og anvendelser deraf
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
UY35903A (es) 2015-07-31
PT3083627T (pt) 2018-11-30
PH12016501198A1 (en) 2016-08-15
MA39186A1 (fr) 2017-11-30
IL246034B (en) 2020-02-27
BR112016014004A2 (zh) 2017-08-08
SG11201604618TA (en) 2016-07-28
WO2015095477A1 (en) 2015-06-25
CA2932870A1 (en) 2015-06-25
TW201609734A (zh) 2016-03-16
US20170333437A1 (en) 2017-11-23
US10596175B2 (en) 2020-03-24
US9303034B2 (en) 2016-04-05
CA2932870C (en) 2021-11-09
PL3083627T3 (pl) 2019-02-28
TWI674263B (zh) 2019-10-11
ES2701087T3 (es) 2019-02-20
CU20160090A7 (es) 2017-05-10
CU24379B1 (es) 2019-02-04
CN106029666A (zh) 2016-10-12
TN2016000253A1 (en) 2017-10-06
KR20160093077A (ko) 2016-08-05
US20160303129A1 (en) 2016-10-20
LT3083627T (lt) 2018-12-27
UA117046C2 (uk) 2018-06-11
EA030823B1 (ru) 2018-10-31
US20190000852A1 (en) 2019-01-03
CY1121060T1 (el) 2019-12-11
BR112016014004B1 (pt) 2022-11-01
AU2014364565A1 (en) 2016-07-14
RS58053B1 (sr) 2019-02-28
NZ721650A (en) 2018-12-21
US10085989B2 (en) 2018-10-02
EA201691271A1 (ru) 2016-12-30
US11123348B2 (en) 2021-09-21
MY175865A (en) 2020-07-14
EP3083627A1 (en) 2016-10-26
US9700559B2 (en) 2017-07-11
US20200179391A1 (en) 2020-06-11
CR20160334A (es) 2016-12-06
SV2016005226A (es) 2019-04-23
MX368072B (es) 2019-09-18
AP2016009329A0 (en) 2016-07-31
AR098844A1 (es) 2016-06-15
EP3083627B1 (en) 2018-09-05
JP2017501177A (ja) 2017-01-12
PE20160865A1 (es) 2016-09-03
CN106029666B (zh) 2018-05-18
MX2016008079A (es) 2016-09-16
JP6392352B2 (ja) 2018-09-19
US20210369716A1 (en) 2021-12-02
ECSP16067921A (es) 2017-10-31
KR102354082B1 (ko) 2022-01-24
HUE040254T2 (hu) 2019-02-28
SI3083627T1 (sl) 2019-01-31
DK3083627T3 (da) 2019-01-02
AU2014364565B2 (en) 2017-06-15
US20150175613A1 (en) 2015-06-25
IL246034A0 (en) 2016-08-02
CL2016001421A1 (es) 2016-12-30
ZA201604415B (en) 2017-09-27
HRP20182021T1 (hr) 2019-01-25

Similar Documents

Publication Publication Date Title
GT201600131A (es) Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DOP2016000140A (es) Inhibidores de syk
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
UY36207A (es) Inhibidores de la syk
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ES2636936T3 (es) Derivados de triazolo[4,5-d]pirimidina para el tratamiento de enfermedades tales como cáncer
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
CO2017011020A2 (es) Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k)
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
CR20170546A (es) Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios
MX362905B (es) Tratamiento de combinacion.
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos
NI201500172A (es) Composiciones farmacéuticas
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.